November 22, 2009

[Company Profile] Pico-Tesla Magnetic Therapies

Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.

November 19, 2009

Echo Therapeutics: Positive Developments for Needle-Free Monitoring System

On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.

November 15, 2009

Burrill Report: Biotech Innovation Gets the Cash

If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.

November 22 2009

ImmunoGen Signs 2nd Licensing Deal with Amgen ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.

November 18 2009

Controversy Over New Breast Cancer Screening Guidelines The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.

November 17 2009

Spherix Shares Rise on Promising Diabetes Drug Data Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.

November 15 2009

Adeona’s Experimental RA Drug Does Well in Phase II Trial Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.

November 11 2009

Ironwood Receives $75M from Astellas for IBS Drug The Cambridge, Mass.-based company has signed a $75 million deal with Astella Pharmaceuticals to market Ironwood’s IBS drug in Asia.

November 10 2009

Avanir Shares Rise on Zenvia Trial Data Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.

November 7 2009

Bioniche Receives $6M Milestone Payment for Bladder Cancer Drug Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.